The bill’s language must be finalized in conference committee prior to being sent to Republican Gov. Greg Abbott.
The measure expands the pool of patients eligible for low-THC therapy to include those diagnosed with: all epilepsy and seizure disorders, multiple sclerosis, spasticity, terminal cancer, incurable neurological disorders (e.g., Alzheimer’s disease, Parkinson’s disease, Huntington’s disease), autism, and amyotrophic lateral sclerosis (ALS).
It also eliminates existing requirements that patients receive approval from a second physician prior to becoming eligible for the state’s access program.
Under existing law, patients diagnosed with intractable epilepsy may register to obtain low-THC (no more than 0.5 percent THC) oils produced by state-licensed manufacturers.